Patents by Inventor Xiufeng Wu

Xiufeng Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132626
    Abstract: The present invention generally relates to Fab-based antibody-like binding proteins comprising three antigen-binding domains that specifically bind one or more target proteins, wherein the antibody domain interfaces are engineered so that they readily self-assemble. The disclosure also provides methods for making trispecific binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 10, 2019
    Publication date: April 25, 2024
    Inventors: Stephen J. DEMAREST, Xiufeng WU
  • Publication number: 20230242671
    Abstract: Multispecific binding proteins that bind a first antigen and a second antigen and methods of purifying multispecific binding proteins.
    Type: Application
    Filed: March 18, 2021
    Publication date: August 3, 2023
    Inventors: Qing CHAI, Xiufeng WU
  • Publication number: 20220318454
    Abstract: The present invention discloses a method and system for a wind stress coefficient expression by comprehensively considering impacts of an average wind speed, a fetch and a water depth, and relates to the field of wind-wave-current numerical simulation studies. Based on a wind-wave-current coupling interaction mechanism in lakes, oceans and other waters, two dimensionless numbers that can represent a wind-wave-current interaction strength: a fetch Froude number and a fetch Reynolds number, are constructed, a form of a wind stress coefficient expression with an undetermined coefficient is established, and then the undetermined coefficient is obtained by using a nonlinear regression method with reference to experimental and measured data to obtain a final wind stress coefficient expression.
    Type: Application
    Filed: January 28, 2021
    Publication date: October 6, 2022
    Inventors: Shiqiang WU, Xiufeng WU, Ang GAO, Chenhui WU, Jiangyu DAI, Fangfang WANG, Yu ZHANG, Zhun XU, Qianqian YANG, Lei YU
  • Publication number: 20220251198
    Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
    Type: Application
    Filed: April 21, 2022
    Publication date: August 11, 2022
    Inventors: Stephen J. Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
  • Patent number: 11319370
    Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: May 3, 2022
    Assignee: Eli Lilly and Company
    Inventors: Stephen J Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
  • Publication number: 20200087395
    Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 19, 2020
    Inventors: Stephen J Demarest, Anja Koester, Scott Charles Potter, Diana Isabel Ruiz, Derrick Ryan Witcher, Xiufeng Wu, Payal Mehta
  • Patent number: 10577415
    Abstract: IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: March 3, 2020
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Stephen John Demarest, Xiufeng Wu
  • Patent number: 10562982
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 18, 2020
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Stephen J Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Publication number: 20190211115
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 11, 2019
    Inventors: Stephen J. Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Patent number: 10294307
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 21, 2019
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Stephen J Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Publication number: 20180319880
    Abstract: IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
    Type: Application
    Filed: April 26, 2018
    Publication date: November 8, 2018
    Inventors: Robert Jan Benschop, Stephen John Demarest, Xiufeng WU
  • Publication number: 20180305466
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain light-chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Application
    Filed: July 6, 2018
    Publication date: October 25, 2018
    Inventors: Stephen J Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Patent number: 10047167
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 14, 2018
    Assignees: Eli Lilly and Company, University of North Carolina at Chapel Hill
    Inventors: Stephen J Demarest, Xiufeng Wu, Brian Arthur Kuhlman, Steven Morgan Lewis, Raheleh Toughiri
  • Patent number: 10003491
    Abstract: Disclosed is a transmission method compatible with higher order modulation and lower order modulation, and an apparatus. A base station stores a first higher order modulation mapping table supporting the higher order modulation and a first lower order modulation mapping table supporting the lower order modulation; the base station receives capability level information sent by user equipment; the base station determines, according to the capability level information sent by the user equipment, a first modulation mapping table used to communicate with the user equipment; the base station determines a modulation and coding scheme index according to the modulation mapping table, where the modulation and coding scheme index is used by the user equipment to determine a modulation and coding scheme; and the modulation and coding scheme index is sent to the user equipment.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: June 19, 2018
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Huaizhi Zhang, Weimin Chen, Xiufeng Wu, Qing Wang
  • Publication number: 20180034679
    Abstract: Disclosed is a transmission method compatible with higher order modulation and lower order modulation, and an apparatus. A base station stores a first higher order modulation mapping table supporting the higher order modulation and a first lower order modulation mapping table supporting the lower order modulation; the base station receives capability level information sent by user equipment; the base station determines, according to the capability level information sent by the user equipment, a first modulation mapping table used to communicate with the user equipment; the base station determines a modulation and coding scheme index according to the modulation mapping table, where the modulation and coding scheme index is used by the user equipment to determine a modulation and coding scheme; and the modulation and coding scheme index is sent to the user equipment.
    Type: Application
    Filed: October 10, 2017
    Publication date: February 1, 2018
    Inventors: Huaizhi ZHANG, Weimin CHEN, Xiufeng WU, Qing WANG
  • Patent number: 9806932
    Abstract: Disclosed is a transmission method compatible with higher order modulation and lower order modulation, and an apparatus. A base station stores a first higher order modulation mapping table supporting the higher order modulation and a first lower order modulation mapping table supporting the lower order modulation; the base station receives capability level information sent by user equipment; the base station determines, according to the capability level information sent by the user equipment, a first modulation mapping table used to communicate with the user equipment; the base station determines a modulation and coding scheme index according to the modulation mapping table, where the modulation and coding scheme index is used by the user equipment to determine a modulation and coding scheme; and the modulation and coding scheme index is sent to the user equipment.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 31, 2017
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Huaizhi Zhang, Weimin Chen, Xiufeng Wu, Qing Wang
  • Patent number: 9698963
    Abstract: The present invention discloses a method for scheduling user equipment on a full-duplex cellular network, including: determining a pairing set for each piece of user equipment in a cell, where a pairing parameter of the piece of user equipment and any piece of user equipment that is in the pairing set of the piece of user equipment meets a preset threshold; and selecting, when a piece of user equipment is scheduled to perform data transmission, another piece of user equipment from a pairing set of the piece of user equipment to perform data transmission in an opposite direction. Embodiments of the present invention further provide a corresponding apparatus. According to the technical solution of the present invention, existing spectrum resources can be utilized more thoroughly and spectrum utilization efficiency of wireless access can be improved.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: July 4, 2017
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Long Luo, Xiufeng Wu, Linjun Lv, Qing Wang
  • Publication number: 20160269218
    Abstract: Disclosed is a transmission method compatible with higher order modulation and lower order modulation, and an apparatus. A base station stores a first higher order modulation mapping table supporting the higher order modulation and a first lower order modulation mapping table supporting the lower order modulation; the base station receives capability level information sent by user equipment; the base station determines, according to the capability level information sent by the user equipment, a first modulation mapping table used to communicate with the user equipment; the base station determines a modulation and coding scheme index according to the modulation mapping table, where the modulation and coding scheme index is used by the user equipment to determine a modulation and coding scheme; and the modulation and coding scheme index is sent to the user equipment.
    Type: Application
    Filed: May 20, 2016
    Publication date: September 15, 2016
    Inventors: Huaizhi ZHANG, Weimin CHEN, Xiufeng WU, Qing WANG
  • Publication number: 20160039947
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 11, 2016
    Inventors: Stephen J Demarest, Xiufeng Wu, Brian Arthur Kuhlman, Steven Morgan Lewis, Raheleh Toughiri
  • Publication number: 20150327293
    Abstract: The present invention discloses a method for scheduling user equipment on a full-duplex cellular network, including: determining a pairing set for each piece of user equipment in a cell, where a pairing parameter of the piece of user equipment and any piece of user equipment that is in the pairing set of the piece of user equipment meets a preset threshold; and selecting, when a piece of user equipment is scheduled to perform data transmission, another piece of user equipment from a pairing set of the piece of user equipment to perform data transmission in an opposite direction. Embodiments of the present invention further provide a corresponding apparatus. According to the technical solution of the present invention, existing spectrum resources can be utilized more thoroughly and spectrum utilization efficiency of wireless access can be improved.
    Type: Application
    Filed: July 21, 2015
    Publication date: November 12, 2015
    Inventors: Long Luo, Xiufeng Wu, Linjun Lv, Qing Wang